About BIOMAP

Towards Personalised Medicine for Inflammatory Skin Diseases

BIOMAP will examine the causes and mechanisms of Atopic Dermatitis and Psoriasis to enable optimal treatments and an individualised therapy scheme for each patient.

Atopic Dermatitis and Psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time and response to treatment.

60 months
Duration

60 months

12 countries
31 Partners

12 countries

20.8 Mio €
Budget

20.8 Mio €

Presentation of the kick off meeting

Videos

Disease Scope

Atopic Dermatitis

3.5%
global annual prevalence
atopic diseases, infections, psychiatric disorders, cardiovascular disease
common comorbidities
80%
heritability

Psoriasis

1.5%
global annual prevalence
arthritis, metabolic syndrome, psychiatric disorders, cardiovascular disease
common comorbidities
70%
heritability

Key Problems

High disease heterogeneity

High disease heterogeneity

Outdated disease classification

Outdated disease classification

Limited understanding of underlying mechanisms

Limited understanding of underlying mechanisms

Lack of biomarkers for disease and therapy prediction

Lack of biomarkers for disease and therapy prediction

Insufficient infrastructure for global access to samples and data

Insufficient infrastructure for global access to samples and data

BIOMAP Vision

To better define the heterogeneity and homogeneous aspects of atopic dermatitis and psoriasis and to develop new concepts for taxonomy and patient stratification

Approach

Network

To form a collaborative network of clinicians, researchers, patient organisations and industry partners

Biosamples

To establish a pan-European BioResource of samples aligned to high quality clinical data

Data Warehouse

To build a Data Warehouse with clinical, experimental and multi-omics data from large high-quality cohorts and industry trials

Data Modelling

To use cutting-edge integrative data modelling approaches